m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03142)
Name
BMS-191095
Synonyms
BMS-199080
    Click to Show/Hide
Status
Discontinued in Phase 1
Structure
Formula
C22H21ClN4O2
InChI
1S/C22H21ClN4O2/c1-22(2)21(28)20(17-11-14(12-24)3-8-18(17)29-22)27(13-19-25-9-10-26-19)16-6-4-15(23)5-7-16/h3-11,20-21,28H,13H2,1-2H3,(H,25,26)/t20-,21+/m0/s1
InChIKey
SMIKIPXIDLITMP-LEWJYISDSA-N
PubChem CID
9822753
TTD Drug ID
D04JGA
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Sulfonylurea receptor 2 (ABCC9)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for BMS-191095. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of BMS-191095 through regulating the expression of Sulfonylurea receptor 2 (ABCC9). [1], [2]
References
Ref 1 TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the Beta-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. Oncogenesis. 2020 May 7;9(5):45. doi: 10.1038/s41389-020-0229-9.
Ref 2 BTS-67582 (Knoll Pharmaceuticals Co). IDrugs. 1999 Apr;2(4):355-9.